Vanda Pharmaceuticals | VNDA - Des Atouts





Des Atouts Changement Date
Acadia Pharmaceuticals USD 1.79B 51.25M 2026-09
Agios Pharmaceuticals USD 1.06B 44.38M 2026-09
Akebia Therapeutics USD 342.13M 7.53M 2026-09
Alnylam Pharmaceuticals USD 7.99B 2.44B 2026-09
Anika Therapeutics USD 183.47M 4.09M 2026-06
Arrowhead Research USD 2.11B 156.25M 2026-06
AstraZeneca USD 119.92B 4.09B 2026-09
Bristol-Myers Squibb USD 88.77B 1.14B 2026-09
Eli Lilly USD 148.07B 5.79B 2026-09
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Halozyme Therapeutics USD 3.47B 895.94M 2026-09
Heron Therapeutics USD 252.26M 6.05M 2026-06
Insmed USD 2.23B 123.49M 2026-09
J&J USD 197.42B 3.64B 2026-09
Lexicon Pharmaceuticals USD 268.82M 83.83M 2026-03
Ligand Pharmaceuticals USD 2.24B 51.59M 2026-09
Merck USD 132.77B 2.97B 2026-09
Minerva Neurosciences USD 97.97M 69.88M 2025-12
Moderna USD 13.47B 2.51B 2026-09
Novartis USD 117.15B 1.38B 2026-09
Pfizer USD 204.54B 3.41B 2026-09
PTC Therapeutics USD 3.21B 42.76M 2026-09
Puma Biotechnology USD 202.86M 7.95M 2025-09
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sanofi EUR 130.29B 1.23B 2026-09
Takeda JPY 15.27T 391.77B 2026-09
Teva Pharmaceutical Industries USD 40.04B 185M 2026-09
Ultragenyx Pharmaceutical USD 1.19B 77M 2026-09
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Veracyte USD 1.57B 86.89M 2026-09